Randomized Trialhigh evidence
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Lancet (London, England)·June 13, 2026·PMID 42250575
Why it mattersRetatrutide is a novel triple agonist (GIP, GLP-1, glucagon) that may offer greater glycemic and weight benefits than existing agents. This trial provides phase 3 evidence for its efficacy and safety as monotherapy in early type 2 diabetes, relevant for metabolic specialists considering next-generation incretin therapies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled